Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of CSR T Cells in PD-L1 Positive Malignant Tumors
NCT02930967Phase 1Unknown
- Sponsor
- Emergency General Hospital
- Start
- Aug 2016
- Primary completion
- Aug 2018
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in pancreatic cancer (PC), renal cell carcinoma (RCC), colorectal cancer (CRC) and 3 more, sponsored by Emergency General Hospital. Primary endpoint: Incidents of treatment related adverse events at 2 years. Status: unknown.
02
Conditions
pancreatic cancer (PC)renal cell carcinoma (RCC)colorectal cancer (CRC)lymphomabreast cancer
Beyond the preview
Go deeper on NCT02930967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02930967.